ABSTRACT
binds to preformed ECD dimers and spontaneous dimerization is the rate-limiting step of the ligand binding process. All the studied peptides, including A71915 antagonist, induce a dosedependent fluorescence homoquenching, specific to dimerization, with potencies highly correlated with their binding affinities. A71915 induced more quenching than other peptides, suggesting stabilization by the antagonist of ECD dimer in a distinct inactive conformation. In summary, these results indicate that the ligand-induced dimerization process of NPRA is different from that for cytokine receptor model. Agonists or antagonists bind to preformed dimeric ECD, leading to dimer stabilization in an active or inactive conformation, respectively. Furthermore, the highly sensitive fluorescence assay designed to assess dimerization could serve as a powerful tool for further detailing the kinetic steps involved in natriuretic peptide receptor binding and activation.
Natriuretic peptides provide an essential counterbalance mechanism to the renin-angiotensin-aldosterone system (Gardner et al., 2007) . Their cardioprotective role is exemplified in gene knockout studies that have shown that they act locally to prevent cardiac hypertrophy (Kuhn, 2004) . Gene polymorphism of atrial natriuretic peptide (ANP) and of natriuretic peptide receptor (NPR) type A has been associated with increased left ventricular mass in essential hypertensive patients (Rubattu et al., 2006) . Natriuretic peptides are currently used as therapeutic agents in the treatment of the acute phase of myocardial infarct (Strain, 2004; Lee and Burnett, 2007) .
ANP cellular action is mediated through NPRA. This receptor is typical of membrane guanylyl cyclases, and it is formed of five domains (Padayatti et al., 2004 ). An extracellular domain (ECD) specifically binds natriuretic peptides in a 2:1 stoichiometric ratio (Rondeau et al., 1995; to the cytoplasmic domain. The cytoplasmic domain includes a kinase homology domain (KHD), which allosterically regulates both peptide binding to the ECD and activation of the effector guanylyl cyclase (GC) (Larose et al., 1991; Duda et al., 2005) . The KHD directly binds ATP after activation of the ECD by ANP (Joubert et al., 2005) . It is also normally phosphorylated, and its dephosphorylation coincides with desensitization of NPRA to ANP activation (Joubert et al., 2001; Potter et al., 2006) . The KHD and the GC domains are connected by a coiled-coil that maintains the catalytic moieties in close contact. The GC domain presents two functional and allosterically regulated catalytic sites whose structure is jointly contributed by both subunits (Joubert et al., 2007) .
The extracellular juxtamembrane region connecting the bilobed ECD to the transmembrane domain seems to play a crucial role in the transmembrane signal transduction mechanism. Mutation C423S disrupts a short intrachain disulfidebridged loop and leads to constitutive activation of NPRA (Labrecque et al., 1999) . The unpaired Cys 432 of this mutant forms an interchain disulfide, showing that the juxtamembrane regions are juxtaposed. However, mutation D435C, three residues downstream of Cys 432 , leads to an agonistinduced disulfide, indicating that a conformational change, either a translation or a rotation of the subunits, is occurring upon activation by ANP ). Crystallographic study of the soluble ECD of NPRA has confirmed this hypothesis (Ogawa et al., 2004) , although no structural documentation of the juxtamembrane region of the ECD was obtained.
The cytokine receptor family displays structural similarities with those of natriuretic peptide receptors. The prototypical growth hormone receptor (GHR) is a homodimeric receptor constituted of an ECD with limited dimerization interface, but with specific binding surfaces for contacting GH, a single transmembrane domain, and a cytoplasmic domain involved in activation of downstream effectors signaling (de Vos et al., 1992) . For this hormone and for all cytokines, a site I on the agonist interacts sequentially with one receptor subunit (Cunningham et al., 1991) . This first contact is followed by the interaction of site II of the ligand with a second receptor subunit, resulting in a more stable complex and in transmembrane activation (Cunningham and Wells, 1993) . GH analogs mutated on site II fail to bind to the second receptor subunit and act as antagonists (Fuh et al., 1992) . In addition, native GH at high concentration binds in a 1:1 stoichiometric ratio, resulting in a bell-shaped doseresponse curve for GH (Cunningham et al., 1991) .
In contrast with cytokines, ANP is not well structured in solution (Carpenter et al., 1997) . However, in the receptorbound state it displays a flat ring moiety tightly interfacing with both ECD subunits, resulting in high-affinity binding (Ogawa et al., 2004) . Whether NPRA ECD is spontaneously monomeric or dimeric in the inactive state is still debated. It has been reported that the soluble ECD of NPRA is monomeric even at micromolar concentration and that it dimerizes only in the presence of ANP (Misono et al., 1999) . However, the sequence of the binding steps of ANP was not defined. We have studied by radioligand binding, FRET homotransfer, and molecular modeling the interaction of NPRA ECD with the agonists rat atrial natriuretic peptide (rANP) and porcine brain natriuretic peptide (pBNP), the superagonist (Arg 10 , Leu 12 ,Ser 17 ,Leu 18 )-rANP-(1-28) (BANP) (Mimeault et al., 1993; Bodart et al., 1996) , the minimized analog (Met 5 , Cys )-rANP-(5-19) amide (mini-ANP) (Li et al., 1995) , and the antagonist A71915 (von Geldern et al., 1990) . The results indicate that ANP binds to preformed ECD dimers and that spontaneous ECD dimerization is the ratelimiting step. In addition, we document that both agonists and the antagonist stabilize the ECD dimeric state, but with different conformations.
Materials and Methods
Materials. rANP 1-28 and C-type natriuretic peptide (CNP) were purchased from Sigma-Aldrich (St. Louis, MO). A71915, mini-ANP, pBNP32, and (Des-Gln 18 ,des-Ser 19 ,des-Gly 20,22 ,des-Leu 21 )-rANP-(4-23)-amide (C-ANF) were obtained from Bachem California (Torrance, CA). BANP (or pBNP1) was synthesized as described previously (Mimeault et al., 1993) . Aprotinin, leupeptin, Pefabloc, and pepstatin were purchased from Roche Diagnostics (Laval, QC, Canada). Oligonucleotides were obtained from BioCorp (Montréal, QC, Canada) .
Construction of Soluble hNPRA-ECD WT and C423S Mutant. Human full-length NPRA clone, formerly inserted into the expression vector pBK-cytomegalovirus (Stratagene, La Jolla, CA) , was used for the construction of deletion mutants containing only the soluble extracellular domain (hNPRA-ECD). A carboxyl-terminal His-Tag epitope (RSHHHHHH) was inserted by polymerase chain reaction mutagenesis at the membraneproximal end of the extracellular domain of hNPRA, beginning at and replacing residue Glu 441 (mature protein numbering), as described for the rat NPRA (Labrecque et al., 1999) . The hNPRA-ECD WT truncation mutant was subcloned into the Sf9 cell expression vector pFastBac1 (Invitrogen Canada Inc., Burlington, ON, Canada). To improve the expression level of the secreted ECD by Sf9 cells, the hNPRA peptide signal was substituted with the melittin peptide signal MKFLVNVALVFMVVYISYIYA, using a synthetic DNA linker replacing the signal peptide up to the first mature residue Gly 1 . The disulfide-bridged hNPRA-ECD C423S mutant was obtained by site-directed mutagenesis, using the QuikChange methodology (Stratagene), as described previously (Labrecque et al., 1999) .
Transfection of Sf9 Insect Cells. Sf9 cells were grown in SF-900 II SFM medium (Invitrogen Canada Inc.) containing penicillin and streptomycin on a rotating shaker at 28°C. For each transfection, 9 ϫ 10 5 cells were seeded in a six-well plate, and cells allowed to attach for at least 1 h. Recombinant Bacmid DNA was transfected into Sf9 insect cells using Cellfectin reagent (Invitrogen Canada Inc.). The Lipid reagent and Bacmid DNA were diluted separately into 100 l of Grace's medium without antibiotics, and they were combined to form lipid-DNA complexes that were incubated at 22°C for 45 min. Medium from Sf9 was removed, and cells were washed with 2 ml of Grace's medium (Invitrogen Canada Inc.). The lipid-DNA complexes were then diluted to 1 ml with Grace's medium, laid over the washed Sf9 cells, and incubated at 28°C for 5 h. The medium was then removed, and cells were incubated for another 72 h in 2 ml of SF-900 II SFM medium containing antibiotics. Medium was collected and clarified by centrifugation at 500g for 5 min. Recombinant baculovirus were harvested from supernatant and amplified by subsequent infection steps in Sf9 cells as described in the pFastBac Kit protocol (Invitrogen Cananda Inc.).
Titration of Recombinant Baculovirus by Expression in Sf9 Cells. To maximize the expression level of hNPRA-ECDs in Sf9 cells, we tested the multiplicity of infection ratio of recombinant baculovirus over Sf9 cells by sequential dilution. In brief, Sf9 cells (5 ϫ 10 5 ) were incubated in 50 ml of SF-900 II SFM medium in 250-ml Erlenmeyer flasks on a rotating shaker for 48 h at 28°C. At the end of the incubation, 2 g/ml each of leupeptin and aprotinin were added, followed by increasing amounts of recombinant baculovirus and the incubation was prolonged for another 72 h. A cocktail of proteases inhibitors (2 g/ml aprotinin, 2 g/ml leupeptin, 2 g/ml pepstatin, 0.2 mg/ml Pefabloc, and 0.1 mM EDTA) was then added, and Sf9 cells were centrifuged at 500g for 5 min at 4°C. The supernatants were collected, and an aliquot was denatured in Laemmli sample buffer and submitted to electrophoresis as described below. After the Western blot (see below), bands corresponding to the protein of interest were evaluated by densitometry. The baculovirus dilution corresponding to the maximum level of expression was used to scale up the production of hNPRA-ECD.
Expression of hNPRA-ECD WT and hNPRA-ECD C423S Mutant in Sf9 Cells. Sf9 cells (5 ϫ 10 8 ) were incubated in 1000 ml of SF-900 II SFM medium in 250-ml Erlenmeyer flasks (100 ml/flask) on a rotating shaker for 48 h at 28°C. In general, 4 ml of recombinant baculovirus was added, and the incubation was prolonged for another 72 h in the presence of leupeptin and aprotinin. After the addition of the protease inhibitors cocktail, the media containing the ECD WT and the ECD C423S were clarified by centrifugation at 500g for 5 min at 4°C and purified to homogeneity. Purification of hNPRA-ECD. The hNPRA-ECD WT and the hNPRA-ECD C423S were dialyzed against 20 volumes of buffer containing 30 mM Tris-HCl, pH 7.4, and 0.1 mM EDTA, and then they were loaded on a 50-ml bed of anionic exchanger quaternary methyl ammonium (Waters, Mississauga, ON, Canada) equilibrated with the dialyzing buffer. The gel was then washed with 5 volumes of 5 mM NaPO 4 , pH 7.4, 30 mM NaCl, and 0.1 mM EDTA, and proteins were eluted with 250 ml of 50 mM NaPO 4 , pH 7.4, 300 mM NaCl, and 0.1 mM EDTA. After addition of 15% glycerol and 10 mM imidazole, the eluate was loaded on a 3-ml nickel-nitrilotriacetic acid column (QIAGEN, Mississauga, ON, Canada). The gel was washed with 30 ml of 50 mM NaPO 4 , pH 7.4, 300 mM NaCl, and 0.1 mM EDTA, and proteins were eluted with 6 ml of the same buffer containing 300 mM imidazole.
The purified ECD was then loaded on 1 ml of ANP-agarose affinity column and washed with 50 mM NaPO 4 , pH 7.4, 300 mM NaCl, and 0.1 mM EDTA. The pure protein was eluted with 5 volumes of 1 ml of 50 mM sodium acetate, pH 5.0, 1 M NaCl, and 0.1 mM EDTA in tubes containing 12 l of 1 M sodium-HEPES to neutralize the pH. The high degree of purity of the hNPRA-ECD was confirmed by Coomassie staining of proteins after analytical SDS-PAGE under reducing and nonreducing conditions. Electrophoresis and Immunoblot Analysis. For the electrophoresis, proteins were solubilized in Laemmli sample buffer (62 mM Tris-HCl, 2% SDS, 10% glycerol, and 0.001% bromphenol blue, pH 6.8) and heated at 100°C for 3 min. For the reducing condition, 5% ␤-mercaptoethanol was added to the sample buffer before boiling. Electrophoresis was performed in 7.5% polyacrylamide gel. Proteins were stained in protein staining solution PageBlue (MBI Fermentas, Burlington, ON, Canada) as specified by the manufacturer. For the Western blot, proteins were electrotransferred from polyacrylamide gel to a nitrocellulose membrane (Bio-Rad, Mississauga, ON, Canada) using the liquid Mini Trans-Blot (Bio-Rad). Detection of hNPRA-ECD was achieved using a Tetra-His Antibody (QIAGEN), and the specific signal was probed with a horseradish peroxidase-coupled secondary antibody, according to the ECL Western blotting analysis system (GE Healthcare, Mississauga, ON, Canada). Under reducing conditions, hNPRA-ECD WT behaves as a 56-kDa protein, whereas hNPRA-ECD C423S showed an apparent molecular mass of 109 and 56 kDa under nonreducing and reducing conditions, respectively.
Radioligand Binding Assays. Competitive binding assays were performed in 200 l of 50 mM NaPO 4 , pH 7.4, 100 mM NaCl, 0.1 mM EDTA, 0.05% lysozyme, 0.1% bovine serum albumin containing 67 fmol (200,000 cpm) and 13 fmol (40,000 cpm) of 125 I-ANP for incubation with the ECD WT and the ECD C423S , respectively. Increasing concentrations of indicated competing peptides were added, and the reaction was initiated by the addition of 7.4 ng (132 fmol of monomer) for the ECD WT and 4.3 ng (39 fmol of dimer) for the ECD C423S . After 22 h at 22°C, the tubes were cooled down at 4°C.
Then, 100 l of the reaction medium was loaded on 1.8 ml of Sephadex G-50 (GE Healthcare) and eluted with 50 mM NaPO 4 , pH 7.4, 100 mM NaCl, and 0.1 mM EDTA. The void volume containing the ECD-bound radioligand was recovered and quantified in a PerkinElmer gamma counter (PerkinElmer Life and Analytical Sciences, Waltham, MA). Kinetic assays were performed under the same conditions as the binding assays. Association was initiated by the addition of 125 I-ANP (0.3 nM and 66 pM for ECD WT and ECD C423S , respectively). Dissociation was initiated by the addition of an excess of unlabeled rANP (1 M). The amount of specific binding was assessed at different times of incubation at 22°C, as described above.
Labeling of Mutant at the Cys 432 with Fluorescent Probe. The residue Cys 432 , which is involved in the interchain disulfide bridge of homodimeric hNPRA-ECD C423S , was used as the specific site for anchoring fluorescent probes. To expose free Cys 423 , 125 g of pure hNPRA-ECD C423S was reduced in 250 l of 50 mM HEPES, pH 7.4, and 0.1 mM EDTA by reacting at room temperature for 10 min with 20 l of 80 mM tris(2-carboxyethyl) phosphine (Promega, San Luis Obispo, CA) in HEPES buffer. After the addition of 12.5 l of dimethyl sulfoxide containing 250 g of Alexa Fluor 488 C5 maleimide (Invitrogen Canada Inc.), the reaction was carried for two additional hours at room temperature, followed by an overnight incubation at 4°C. The labeled protein was separated from unreacted fluorophore by gel permeation chromatography on PD-10 column (GE Healthcare) using 50 mM NaPO 4 , pH 7.4, 100 mM NaCl, and 0.1 mM EDTA as eluant. The final cleaning of the hNPRA-ECD-AF488-labeled protein was achieved by chromatography on nickel-nitrilotriacetic acid column as described above. The protein was aliquoted and kept frozen at Ϫ80°C in 10% glycerol until used.
Measurement of ECD Dimerization by FRET Homotransfer. We preincubated 17.6 ng (332 fmol of monomer) of hNPRA-ECD-AF488 in 100 l of 50 mM NaPO 4 , pH 7.4, 100 mM NaCl, 0.1 mM EDTA, 0.05% lysozyme, 0.1% bovine serum albumin, and Tween 0.01% for 60 min at 22°C in black untreated 96-well (Corning Inc., New York, NY). Then, 100 l of increasing concentrations of indicated peptides were added, and the plates were placed on a rotating shaker for 20 s and incubated at 22°C for another hour in the dark. The fluorescence was then measured for 5 s, using a Victor 2 multilabel counter (PerkinElmer Life and Analytical Sciences) with the excitation filter set at 485 nm. The fluorescence was recorded at 535 nm for 5 s. Net fluorescence was corrected by subtraction of background values measured in the absence of ECD protein.
Molecular Modeling of NP-hNPRA-ECD. All calculations were performed using the software package SYBYL (Tripos, St. Louis, MO). The Tripos force field was used for energy calculations, and a dielectric constant of 1 was used. The X-ray crystal structure of rANP 7-27 bound to the rat NPRA dimer (Ogawa et al., 2004 ) was used as a template for the receptor-bound form of hNPRA-ECD. Each variable amino acid within the ECD dimer complex was replaced one at a time by its equivalent in hNPRA sequence. The backbone dihedral angles were held fixed to preserve the receptor's secondary structure, whereas the amino acid side chains were positioned using the scan subroutine in SYBYL. This routine rotates each side chain dihedral angle until a sterically acceptable conformation was obtained. The complex was then energy minimized for 1000 steps. No major conformational changes were observed during the minimization process. Modeling of the superagonist BANP bound to hNPRA was based on the contact points found using the photoaffinity results reported previously . Both backbone and side chain dihedral angles of these residues were manipulated until steric complementarity with the receptor dimer was obtained and the required ligand-to-receptor contact was formed. At this point, the complex was again subjected to 1000 steps of minimization. For modeling of the antagonist A71915 bound to hNPRA, the NPRA-bound structure of rANP 7-27 reported (Hogawa et al., 2004) was properly modified by deletion and substitution to yield the shorter 11 residue disulfidebridged loop. Conserved residues between A71915 and rANP 7-27 Dimerization of NPRA Extracellular Domain 433 at ASPET Journals on July 11, 2017 molpharm.aspetjournals.org
were then placed at equivalent positions in the binding cleft of the receptor dimer. The complex was then adjusted for steric complementarities with the receptor, and it was subjected to 1000 steps of minimization.
Data Analysis and Statistics. Dose-response curves were analyzed by nonlinear least-squares regression using the four-parameter logistic equation (De Lean et al., 1978) .
where X is the concentration of agent, Y is the response measurement, A is the basal response value in the absence of agent, and D is the maximal response value at high concentration of agent. B is the slope factor of the curve, and C is the concentration of agent at 50% response level. Radioligand binding saturation and competition curves were analyzed by nonlinear least-squares regression using a model based on the law of mass action for the binding of two ligands to a single class of receptor sites (DeLean et al., 1982) . Radioligand binding association kinetics data were analyzed using a model for second order ligand binding to a single class of sites (Rodbard, 1973) :
where
B 0 equals initial binding at time 0 of association kinetics; k on and k off are the association and dissociation constants, respectively; and t is time since the beginning of association kinetics. Dissociation kinetics data were analyzed using a model for a single exponential component.
Statistical testing of repeat experiments was performed by analysis of variance, followed by post hoc Dunnett's or Student-NewmanKeuls test. The logarithmic transform of IC 50 values were used for statistical tests in the case of competition binding and fluorescence quenching studies.
Results
Characterization of Soluble hNPRA-ECD WT and C423S Mutant. Expression of the rat extracellular domain of NPRA in mammalian cell lines has been described previously (Labrecque et al., 1999; Misono et al., 1999) . Based on size-exclusion chromatography, the rat NPRA-ECD behaved in solution as a monomer in the absence of ANP and as a dimer in the presence of ANP (Misono et al., 1999) . Expression of human NPRA-ECD in human embryonic kidney-293 cells proved to be more difficult, and they produced a low yield (data not shown). We therefore expressed the human ECD in Sf9 cells, after replacement of the original signal peptide sequence by that of melittin and by addition of a carboxyl-terminal hexahistidine tag. The secreted ECD was harvested in the Sf9 cell culture medium, and it was purified by metal-chelate and affinity chromatography. The pure ECD monomer was obtained at a decent level (100 g/l) . Microsequencing of the amino-terminal of the ECD documented the expected sequence of the mature form [GN-LT(V)AVVLP. . . ], confirming that cleavage of the melittin signal peptide was properly processed in Sf9 cells. The protein displayed a single homogeneous band of 56 kDa on PAGE (Fig. 1) , suggesting that the protein core (ϳ50 kDa) was glycosylated in this expression system. However, detection of Asn 2 by microsequencing confirmed that this residue was not glycosylated.
We have formerly documented that mutation C423S of rat NPRA disrupts a short disulfide-bridged decapeptide and exposes an unpaired Cys 432 , which covalently dimerizes NPRA in a manner reminiscent of that of clearance-type receptor NPRC (Labrecque et al., 1999) . This mutation also constitutively activates NPRA. It also provides a covalent dimeric form of the soluble NPRA-ECD with an affinity for ANP that is similar to that of full-length NPRA (Labrecque et al., 1999) . This mutation was applied to human NPRA-ECD. It yielded a homogeneous 106-kDa band on nonreducing PAGE (Fig. 1) , with very little monomeric form. hNPRA-ECD C423S was more easily purified, and it was more avidly retained on ANP affinity gel than NPRA-ECD WT , presumably because of its covalently dimeric state and its higher affinity for ANP.
Equilibrium Binding and Kinetics of ANP on NPRA-ECD WT and C423S Mutant. Soluble hNPRA-ECD WT proved to be fully competent under equilibrium binding conditions, with a dissociation constant (K d ) of 7.9 ϫ 10 Ϫ10 M for ANP (Table 1) . As expected for a soluble monomeric ECD, this affinity is somewhat lower than that documented for membrane hNPRA (K d of 1.3 ϫ 10 Ϫ10 M; Bodart et al., 1996) or intact cell receptor (K d of 1.6 ϫ 10 Ϫ10 M; Jewett et al., 1993) . In contrast, the disulfide-bridged hNPRA-ECD C423S displayed a significantly higher affinity (K d ϭ 1.3 ϫ 10 Ϫ10 M; p Ͻ 0.01; Table 1) than that for the WT form. This higher affinity of the C423S mutant matched that for the membrane receptor, again strongly suggesting that functional NPRA is naturally dimeric (Labrecque et al., 1999) .
For cytokine homodimeric receptors, such as GHR, and heterodimeric receptors, such as type I interferon receptor, ligand binding proceeds sequentially in two steps. Cytokines interact with one receptor subunit of the ECD. Then, dimer- ization of the ECD increases affinity for the ligand by slowing down the k off of the cytokine (Cunningham et al., 1991; Lamken et al., 2004) . To test whether this mechanism applies to homodimeric NPRA, we compared the association and dissociation kinetics of ANP to NPRA-ECD WT and C423S mutant ( Fig. 2 (Schlosshauer and Baker, 2004) . However the association kinetics displayed a slight deviation from a second order reaction, and it could be compatible with a two-step process. This suggested that a rate-limiting step was involved, which might correspond to dimerization of the ECD monomers. The dissociation kinetics of ANP from the ECD-WT was very slow and monophasic, with a single k off of 7.6 ϫ 10 Ϫ5 s Ϫ1 . In the covalently dimeric ECD C423S mutant, association kinetics of ANP was monophasic, with a 16-fold faster k on of 6.6 ϫ 10 6 M Ϫ1 s Ϫ1 , strongly suggesting that the rate-limiting step required for dimerization of the ECD was absent for this mutant. However, the dissociation rate constant k off of 8.4 ϫ 10 Ϫ5 s Ϫ1 was very similar to that for the ECD WT . These results contrast with those obtained for cytokine receptors, and they indicate that a different mechanism probably occurs for NPRA. A plausible scheme would involve the binding of ANP to preformed ECD dimers. Kinetically derived estimates of K d , calculated as the ratio k off /k on , deviate from estimates obtained with equilibrium binding results (Table 1) . Such a discrepancy is not uncommon, and it suggests that a more complex binding process is occurring for the ECD WT and ECD C423S mutant, possibly involving fast rebinding of ANP while still in its active conformation.
Specificity of Binding for Natriuretic Peptide Agonists and Antagonist. In contrast with rNPRA, hNPRA is highly selective for full-length ANP 1-28 (Schoenfeld et al., 1995) . hANP and rANP have nearly identical potencies on hNPRA. However, hANP contains a unique residue Met 12 that is oxidized under experimental conditions, leading to a potency loss. Therefore, rANP was preferred as a reference ligand. hBNP is ϳ8-fold less potent than ANP, and even ϳ2-fold weaker than pBNP32. CNP, the NPRB-selective peptide, is inactive at submicromolar concentrations. To check whether the soluble hNPRA-ECD could maintain the peptide binding properties of membrane receptor, we tested the specificity of soluble hNPRA-ECD, using a series of natural natriuretic peptides and analogs with agonist and antagonist properties (Table 2; Fig. 3 ). rANP was ϳ10-fold more potent than pBNP32, whereas CNP, which is specific for NPRB, and C-ANF, which is specific for NPRC, were inactive.
It is noteworthy that, BANP, which is a chimeric peptide with the cyclic portion from pBNP32 and the exocyclic segments from ANP, proved to be 13-fold more potent than the natural ligand ANP. This confirms the unique properties of this superagonist that we have reported previously (Mimeault et al., 1993; Bodart et al., 1996) . Testing of the kinetics of BANP binding to hNPRA-ECD WT indicated that the The amount of specific binding was assessed at different times of incubation at 22°C as described under Materials and Methods. ANP binding is expressed as a fraction of equilibrium binding. Each data point represents the mean Ϯ S.E. of duplicate determinations. The results are representative of at least three identical experiments. Association and dissociation kinetics curves were fitted using models described under Materials and Methods. Kinetic parameters are shown in Table 1 .
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at ASPET Journals on July 11, 2017 molpharm.aspetjournals.org higher affinity of the superagonist is due to both a 10-fold faster k on (7.4 Ϯ 1.6 ϫ 10 6 M Ϫ1 s Ϫ1 ; data not shown) and a slower k off (Ͻ10 Ϫ5 s Ϫ1 ; data not shown), compared with rANP (Table 1) . The size-reduced mini-ANP (Li et al., 1995) proved to be ϳ9-fold less potent than ANP. In addition, we tested the potency of the small peptide antagonist A71915 (von Geldern et al., 1990) in this system. A71915 displayed micromolar affinity and completely inhibited ANP binding at 10 M (Fig. 3; Table 2 ). The potency order BANP Ͼ ANP Ͼ BNP ϳ mini-ANP Ͼ Ͼ A71915 Ͼ Ͼ CNP ϳ C-ANF confirms that the ECD provides a reliable model for the peptide binding site of hNPRA.
Dimerization of ECD WT . We have shown previously (Rondeau et al., 1995) that ANP is binding to NPRA homodimeric subunits in a 1:2 stoichiometric ratio and that a single peptide is contacting both monomers. This was later confirmed by crystal structure determination (Ogawa et al., 2004) . Misono et al. (1999) have documented by size-exclusion chromatography that soluble rat NPRA-ECD behaved as monomer in the ligand-free state, but as a homodimer when bound to ANP. However the ligand specificity of the dimerization process was not established. Therefore, we established a homogeneous assay for soluble hNPRA-ECD that enables measurement in solution of the dimerization state without phase separation. Covalently dimeric hNPRA-ECD C423S was monomerized by reduction with tris(2-carboxyethyl)phosphine and derivatized on free Cys 432 with Alexa Fluor 488-maleimide. The residue Cys 432 is normally located in a decapeptide disulfide-bridged loop under the membrane-proximal lobe of the ECD. Mutation C423S disrupts the loop, resulting in a flexible region with poorly defined secondary structure and leaving Cys 432 exposed and reactive. The resulting fluorescent ECD monomer behaved in ANP binding assays with the same affinity as for underivatized hNPRA-ECD WT (data not shown). Ligand-induced dimerization of the derivatized ECD is expected to bring the two fluorophores of the subunits close together (Ͻ50 Å). At this short distance, fluorescence resonance energy homotransfer (autoquenching) should reduce overall fluorescence (Tricerri et al., 2001) . As shown in Fig. 4 , addition of ANP significantly inhibited fluorescence, directly documenting in solution ligand-induced dimerization without any perturbation by a separation step. The addition of as small as a 1.4-fold excess of underivatized monomeric ECD WT drastically reduced the proportion of fluorescent ECD homodimer to 18% of control (Fig. 4) . Addition of ECD WT lead to an almost complete reversal of fluorescence autoquenching induced by ANP. Addition of ECD WT in the absence of ANP also slightly but significantly increased fluorescence (Fig. 4) . This strongly suggests that a small portion of ECD is spontaneously dimeric even in the absence of ANP. Attempts to document ANP-induced dimerization of hNPRA-ECD by FRET heterotransfer using Alexa Fluor 350 and Alexa Fluor 488 as the donor-acceptor pair confirmed those results (data not shown). However, this heterotransfer system was much less sensitive than with homotransfer, and it required at least 20-fold higher concentrations of derivatized-ECD. Therefore, autoquenching based on Alexa Fluor 488-derivatized ECD was used for subsequent studies.
Because agonists are expected to bind to hNPRA-ECD as a homodimeric receptor, we then tested the specificity of natriuretic peptides and analogs in inducing autoquenching observed with ANP. As shown in Fig. 5 and Table 2 , agonists dose-dependently inhibited fluorescence with a potency order BANP Ͼ ANP Ͼ BNP Ͼ mini-ANP. Potency estimates of peptides on fluorescence quenching was highly correlated (r ϭ 0.99; p Ͻ 0.002) with those for ANP binding competition when expressed on a logarithmic scale ( Table 2 ), indicating that high-affinity binding involves the dimeric state of hN-PRA-ECD. The NPRB-selective peptide CNP was inactive, even at micromolar concentrations. It is noteworthy that the antagonist A71915 also inhibited fluorescence, indicating that the antagonist is binding to a homodimeric form of hNPRA-ECD. This contrasts with the results obtained for GH antagonists, which bind to GHR monomer and fail to induce receptor dimerization (Cunningham et al., 1991; Cunningham and Wells, 1993) . In addition, dose-response curves for autoquenching all displayed a lower plateau at high peptide concentration (Fig. 5) , indicating that excess peptide could not lead to receptor ECD monomerization. This is again in contrast with GHR (Cunningham et al., 1991) , for which GH favors receptor dimerization only at low concentration. This would be expected for such a system where the agonist first binds with high affinity to an ECD monomer, followed by ECD dimerization, which further increases the affinity for the agonist. The absence for ANP and analogs of any high concentration reversal of dimerization strongly argues that natriuretic peptides, agonists, or antagonists essentially bind to preformed dimeric ECD.
The maximum level of autoquenching obtained at high concentration of peptides was quite reproducible for each peptide, but it clearly differed among them ( Table 2 ). The maximal quenching for the agonist pBNP32 and the antagonist A71915 highly significantly differed from that of ANP and BANP. The higher quenching observed is consistent with a smaller distance between the ECD subunits (Tricerri et al., Fig. 5 . Dose-response curves of peptides on FRET homotransfer. Increasing concentrations of indicated peptides were added to hNPRA-ECD-AF488 (1.66 nM monomer), and fluorescence was measured after 1 h of incubation at 22°C, as described under Materials and Methods. Fluorescence is expressed as mean Ϯ S.E. of four determinations. The results are representative of at least three identical experiments. IC 50 and F/F 0 values for these peptides are shown in Table 2 . 125 I-ANP (0.33 nM) and varying concentrations of indicated competing unlabeled peptides for 22h at 22°C, as described under Materials and Methods. ANP binding is expressed as a fraction of initial binding B 0 in absence of competing peptides. Each data point represents the mean Ϯ S.E. of duplicate determinations. The results are representative of at least three identical experiments. The curves were analyzed by nonlinear least-squares regression as described previously (De Léan et al., 1982) . IC 50 values for these peptides are shown in Table 2 . . Thus, although all peptides bind to a dimeric form of the ECD, the conformation of the ECD dimer seems to differ among agonists and especially between the agonists and the antagonist.
Molecular Modeling of NP-NPRA-ECD Complex. The crystal structure of rNPRA-ECD bound to rANP 7-27 has been reported previously (Ogawa et al., 2004) . The truncated peptide used, equivalent to atriopeptin II ], lacks the exocyclic amino-terminal and the carboxyl-terminal residue Tyr 28 . It displays low potency, especially on hNPRA (Schoenfeld et al., 1995) . Nevertheless, it exemplifies the flat conformation of the natriuretic peptide ring, which is tightly bound in the cleft between the ECD subunits. Because hN-PRA and rNPRA sequences mostly differ in their ECD portion and because their affinities for natriuretic peptides are also divergent (Schoenfeld et al., 1995) , it was necessary to derive a structural model for the hNPRA ECD and to compare it with that for rNPRA ECD. Such a model is expected to document the interactions between the peptides and the receptor subunits. It might explain the higher affinity of the superagonist BANP relative to ANP. The model could also document the peculiar positioning of the antagonist A71915 within the peptide binding cleft. All residues of the ECD that differ between hNPRA and rNPRA were properly substituted, and the resulting model, bound to ANP 7-27, was energy-minimized ( Fig. 6A ; Table 3 ). The peptide was then replaced by a previously documented conformation of the superagonist BANP or by modifying ANP into the antagonist A71915 (Fig. 6 , B and C; Table 3 ). Two outstanding regions of the ligand binding interface of natriuretic peptide receptors involve hydrophobic regions (He et al., 2006 (Fig. 6B ). This contrasts with the positioning of the carboxyl-terminal residues of the truncated ANP 7-27, which binds over and occupies the position of the amino-terminal portion of full-length natriuretic peptide ( Fig. 6A ; Table 3 ). This suggests that the expected conformation of the exocyclic portions of native ANP 1-28, which includes both amino-and carboxyl-terminal segments, is more accurately represented by the complex obtained with BANP (Fig. 6B ). This is in agreement with previous observations on the contribution of both the amino-and the carboxyl-terminal to the potency of ANP on human NPRA (Schoenfeld et al., 1995) . Several residues of the cyclic portion of BANP (Arg 11 ,Leu 12 , Ile 15 ,Ser 17 ) interact with different residues of the receptor than those for ANP 7-27 (Table 3) . This might contribute to the higher affinity and potency of BANP relative to ANP, because the ring portion of the natriuretic peptides is central to their tight interaction with NPRA. Docking of the antagonist A71915 indicates that, despite the fact that this antagonist is approximately half the size of full-length agonists such as ANP or BANP, a single molecule of the ligand could fit in the binding cleft (Fig. 6C) . It is noteworthy that the interactions of the crucial residues FG-GRFRI of the ring portion seem to be conserved for A71915. However, residue D-Tic 16 seems to constraint binding of the peptide and to result in a suboptimal fitting with hydrophobic pocket 2. This might possibly explain the antagonistic character of A71915. It is also likely associated with the closer dimer conformation documented by FRET autoquenching ( Fig. 5 ; Table 2 ).
Discussion
We have shown that natriuretic peptide binding to NPRA does not conform to the cytokine receptor model exemplified by GHR. In contrast to cytokines, which present a well defined secondary structure both in the free and the receptorbound states, natriuretic peptide conformation is disordered in solution (Carpenter et al., 1997) . When binding to NPRA, the peptides must acquire a flat penny-like conformation by selection or induction. Perhaps because of their stable conformation in solution, cytokines first bind with nanomolar affinity to one receptor subunit. Interaction with the second receptor subunit then stabilizes the high-affinity dimer, resulting in a slower dissociation rate. However, at higher concentration, two molecules of cytokines can bind their homodimeric receptor, resulting in its monomerization and in loss of activation. Again in contrast with cytokines, natriuretic peptides seem to bind only to a preformed dimeric state of NPRA. This is documented by the flat high-dose asymptote of the homoquenching dose-response curve, which occurs for all peptides (Fig. 3) , contrasting with GHR (Cunningham et al., 1991) .
Slower and apparently more complex association kinetics of ANP to soluble ECD WT than to covalently dimeric ECD C423S indicates that spontaneous dimerization constitutes the rate-limiting step of the ligand binding process (Fig.  7) . In contrast with the conclusions of a previous report (Misono et al., 1999) , it is proposed that ECD WT dimers are present in solution at submicromolar concentration. However, the fast monomerization constant (k mon ) would preclude the documentation of spontaneous dimers in assay systems involving phase separation such as size exclusion chromatography. The use of a homogeneous assay involving FRET homoquenching provided the first evidence for spontaneous dimer formation at nanomolar concentration of ECD (Fig. 4) . Further documentation of the kinetic properties of the dimerization and the ligand binding steps will be required to completely characterize this proposed mechanism (Fig. 7) . Binding of natriuretic peptides to NPRA-ECD is quite stable (Fig. 1; Table 1 ). The affinity of ANP for the covalently dimeric soluble ECD C423S closely mimics that observed with full-length cellular NPRA. This agrees with previous results obtained with rNPRA-ECD (Labrecque et al., 1999) , and with previous observations that full-length NPRA is spontaneously homodimeric.
The correlation of the rank order of potency for natriuretic peptides in ligand binding (Fig. 3) and ECD dimerization assays ( Fig. 4 ; Table 2 ) again confirms that all natriuretic peptides bind to the dimeric state of the ECD. The lower potency of the antagonist A71915 could be interpreted as being due to its smaller size (13 versus 28 residues for ANP). However, the agonist mini-ANP (15 residues) still conserves high affinity, albeit reduced relative to that for full-length ANP. Thus, the lower affinity of A71915 might be due to its altered conformation. For erythropoietin receptor, both agonists and antagonists also bind to the dimeric form of the receptor (Syed et al., 1998) . However, the conformation of the receptor dimer differs between various ligands. Our results on distinct maxima of fluorescence autoquenching ( Fig. 5 ; Table 2 ) also show that the conformation of the ligand-bound NPRA-ECD dimer differs among peptides. The antagonist A71915 mostly differs from the results for ANP (Table 2) . This would be compatible with a shorter distance between the fluorophores located in the carboxyl-terminal region of the ECD. This might be associated with an axial or a lateral rotation of the ECD subunits, leading to an inactive conformation of the receptor. The constrained interaction of residue D-Tic 16 of A71915 with hydrophobic pocket 2 of the ECD is potentially associated with the antagonistic properties. Indeed, substitution in A71915 of with the natural residue L-Phe 16 leads to the full agonist A68828 (von Geldern et al., 1992) .
The conformational change occurring during activation of NPRA is still unknown. Agonist binding to the homodimeric ECD seems to alter the positioning of the receptor subunits, possibly according to a rotation mechanism (Ogawa et al., 2004) . This was predictable based upon previous results using cysteine substitution of the extracellular juxtamembrane domain. Mutation C423S of NPRA, leading to an unpaired Cys 432 , results in spontaneous disulfide bridge formation, indicating that the juxtamembrane regions of the ECD subunits should be juxtaposed (Labrecque et al., 1999) . However, mutation D435C, producing an unpaired Cys 435 three residues distal to Cys 432 , leads to a disulfide bridge only upon NPRA activation by ANP . These results are compatible with a conformational change of the juxtamembrane domain that was also documented in the present work by FRET autoquenching. Whether this change is due to an axial rotation or to a lateral movement of the The subunits of the soluble extracellular domain are represented as two connected lobes (dark gray), with the membrane distal lobes interfacing each other when in the peptide-bound state. The plasma membrane (not shown) is assumed to be located below the ECD. The peptide ligand is presented as a small ellipse (light gray). The fast rates for the monomerization of the ECD (k mon ) and the association (k on ) of the ligand to the preformed ECD dimer are represented as thick arrows. The slow rates for ECD dimer formation (k dim ) and peptide dissociation (k off ) are shown as thin arrows.
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at ASPET Journals on July 11, 2017 molpharm.aspetjournals.org subunits is not yet clear. For cytokine receptors, one prevalently proposed activation mechanism involves subunit rotation within a receptor dimer (Brown et al., 2005) . The structure of the juxtamembrane region of NPRA-ECD is not well documented in the reported crystallographic studies of soluble ECD. The proper conformation of this region is probably dependent on its natural proximity to the plasma membrane, and it should ultimately be studied in the presence of a phospholipid bilayer. Further studies will be required for documenting this activation conformational change of NPRA. The homogenous FRET assay described in this study provides a new experimental approach for detailing the kinetic steps involved in natriuretic peptide receptor binding and activation. Its high sensitivity and accuracy could also prove valuable in the study of agonist-and antagonist-specific conformations of the receptor.
